Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms
Jie Qian(Nanjing Medical University), David J. Burns, Jeffrey R. Huth(Abbott Fund), Kenneth M. Comess(Abbott (United States)), Andrew M. Petros(Abbott Fund), Usha Warrior(Abbott (United States)), Michael Coen, Haichao Zhang(Abbott Fund), Martin J. Voorbach(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Shi‐Chung Ng(Ligand Pharmaceuticals (United States))
Cited by 71
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k